Protokinetix, INC

ProtoKinetix appoints Dr. Keith Brunt as President and Director while announcing a $253 million valuation for its ophthalmic patent portfolio.

ProtoKinetix, Incorporated announced a leadership transition following the passing of Clarence Smith, with Michael Guzzetta now serving as CEO, reaffirming the company's commitment to its AAGP molecule development.

ProtoKinetix, a clinical-stage biomedical company, announced the tragic death of its President and CEO, Clarence E. Smith, and the immediate appointment of Michael Guzzetta as his successor.

ProtoKinetix, Incorporated announces the tragic death of its President and CEO, Clarence E. Smith, and the immediate appointment of Michael Guzzetta as his successor.

ProtoKinetix, Incorporated stockholders approved an amendment to increase the total authorized common stock from 500 million to 600 million shares.

ProtoKinetix, a development stage biotech, reported increased losses and a significant accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite a slight improvement in cash position.

ProtoKinetix, a development stage medical research company, reported an increased net loss and worsening negative working capital in its Q2 2025 filing, highlighting ongoing reliance on equity financing despite a slight cash increase.

ProtoKinetix, a development stage biotechnology company, announced its financial results for the first quarter of 2025, highlighting its continued focus on commercializing its AAGP molecule.

ProtoKinetix, a development-stage biotech company, reported a net loss of $261,676 for the nine months ended September 30, 2024, with a decrease in operating expenses and a focus on securing strategic partnerships for its AAGP molecule.

ProtoKinetix, a development stage company, reported a reduced net loss for the six months ended June 30, 2024, compared to the same period in 2023, while continuing to focus on the commercialization of its AAGP technology.

ProtoKinetix, a development stage company, reported a net loss of $92,026 for the first quarter of 2024, with ongoing efforts to secure additional funding for research and development.

ProtoKinetix's 2024 10-K filing reveals increased operating losses and substantial doubt about the company's ability to continue as a going concern, despite reduced research and development spending.

ProtoKinetix, a biotechnology company focused on AAGP research, released its 10-K filing, outlining its financial status, research activities, and future plans.

Clarence Smith, President and CEO of ProtoKinetix, Inc., reports the acquisition of 2,000,000 shares of common stock through a private placement.

Clarence Edward Smith, President & CEO of ProtoKinetix, Inc., reports the acquisition of 6,500,000 shares of common stock through a private placement.

Clarence Edward Smith, President & CEO of ProtoKinetix, Inc., reports acquisition of additional shares through private placements.

ProtoKinetix, Incorporated is soliciting stockholder consent to increase its authorized common stock from 500 million to 600 million shares to facilitate future capital raises for working capital and general corporate purposes.